US FDA approves AstraZeneca’s diabetes drug for treating heart failure risk
The approval by the US Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial
AstraZeneca said US regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.
The approval by the US Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval by the European authorities in August.
Diabetes is associated with a high risk of heart failure.
- Advertisement -